Nurix Therapeutics, Inc.
Nasdaq: NRIXPharmaceutical Preparations · Entity-resolved by Clous
CIK0001549595
TickerNRIX
ExchangeNasdaq
SIC2834
StateDE
FY end11-30
Illustrative profile — live data lights up when a server API key is configured.
Key financials
RevenueFY2025-11-30
$83.98M
+54.0% YoY
Net IncomeFY2025-11-30
-$264.46M
-36.6% YoY
Total AssetsFY2025-11-30
$688.14M
+2.8% YoY
EquityFY2025-11-30
$538.75M
+2.2% YoY
Shares OutstandingFY2025-11-30
102.84M
—
Operating Cash FlowFY2025-11-30
-$249.47M
-44.5% YoY
Market
Market
NRIXClose price
$17.57
Market cap
$1.82B
delayed EOD · as of 2026-06-18
Short interest & fails
Cost to borrow0.41%700K shares availablegeneral collateral
Short-sale volume
FINRA Reg SHO · daily68.5%
short of total volume · 2026-06-18
2026-06-1868.5%
2026-06-1756.3%
2026-06-1673.4%
2026-06-1564.0%
2026-06-1269.8%
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
| Concept | FY2022-11-30 | FY2023-11-30 | FY2024-11-30 | FY2025-11-30 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | — | — | $54.55M | $83.98M | +54.0% | 100% |
| Net Income | -$180.36M | -$143.95M | -$193.57M | -$264.46M | -36.6% | -315% |
| Total Assets | $416.76M | $355.6M | $669.34M | $688.14M | +2.8% | 819% |
| Equity | $303.7M | $200.49M | $526.99M | $538.75M | +2.2% | 642% |
| Operating Cash Flow | -$159.81M | -$81.37M | -$172.58M | -$249.47M | -44.5% | -297% |
| Shares Outstanding | — | — | — | 102.84M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001549595